Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538733 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00538733 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 26 participants.
The verdict
NCT00538733, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). 2. Evaluate the efficacy of the addition of thalidomide (Thalomid®) to BiRD combination therapy as a therapy to increase the complete response rate for patients with newly diagnosed multiple myeloma. 3. Evaluate the safety of the combination of clarithromycin, lenalidomide, dexamethasone, and thalidomide as a therapy for patients with newly diagnosed MM
Interventions
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG clarithromycin
- DRUG thalomid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-10 |
| Est. Completion | 2020-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538733
The ClinicalTrials.gov registry entry for NCT00538733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00538733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00538733 about?
NCT00538733 is a clinical study titled "Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma". Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). 2. Evaluate the efficacy of the addition of tha...
What is the current status of trial NCT00538733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-10. Estimated completion is 2020-09-17.
What interventions are being tested in trial NCT00538733?
The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG), clarithromycin (DRUG), thalomid (DRUG).
Who is sponsoring clinical trial NCT00538733?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.